Posted by Michael Wonder on 16 Sep 2017
Meeting highlights from the CHMP 11 to 14 September 2017 meeting
15 September 2017 - Thirteen medicines recommended for approval, including one orphan medicine,
The European Medicines Agency’s CHMP recommended thirteen medicines for approval at its September meeting.
The CHMP recommended granting marketing authorisations for two cancer medicines: Zejula (niraparib), an orphan designated medicine intended for the treatment of ovarian cancer, and Tookad (padeliporfin), for the treatment of adenocarcinoma of the prostate.
Two medicines for the treatment of adults with moderate to severe chronic obstructive pulmonary disease also received a positive opinion from the Committee: Elebrato Ellipta (fluticasone furoate / umeclidinium / vilanterol) and Trelegy Ellipta (fluticasone furoate / umeclidinium / vilanterol).
